What will this webinar address?

Immunology represents the fastest-growing therapy area in 2021, more so even than oncology. Innovations in targeted therapies have contributed significantly to this growth rate, although this innovation is focused more in some diseases than others. Understanding the immunology market at a disease level allows for a greater insight into where there are potential areas of unmet need.

In the respiratory market we see a rapid growth of biologics for a range of diseases, which is reflecting the majority of value growth in the therapy area. In the small molecule area the primary growth driver are triple therapies, which are a fairly new entry to the market.

This webinar will enable a more in-depth analysis of both immunology and respiratory sales at a disease level, using MIDAS Sales by Disease to understand the drivers of growth and diseases in focus.

Why attend?

• To gain an overview of the respiratory and targeted immunology markets including growth and value
• Understand the multi-indicational nature of the targeted immunology market
• Learn how MIDAS Sales by Disease can be used to generate analyses of sales at a disease level

To get some initial insights on the immunology market, read our recent Sales by Disease blog HERE.

Speakers

Aaron Wright
Analyst, IQVIA European Thought Leadership

Tom Woods
Consultant, IQVIA European Thought Leadership